Vanguard Group Inc. grew its stake in shares of Advaxis, Inc. (NASDAQ:ADXS) by 7.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,782,990 shares of the biotechnology company’s stock after buying an additional 119,980 shares during the quarter. Vanguard Group Inc. owned 4.41% of Advaxis worth $11,572,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of ADXS. Parametric Portfolio Associates LLC raised its position in shares of Advaxis by 116.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 86,586 shares of the biotechnology company’s stock valued at $707,000 after buying an additional 46,559 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Advaxis during the 2nd quarter valued at $201,000. Stonebridge Capital Management Inc. purchased a new stake in shares of Advaxis during the 2nd quarter valued at $146,000. Alliancebernstein L.P. raised its position in shares of Advaxis by 44.8% during the 2nd quarter. Alliancebernstein L.P. now owns 67,900 shares of the biotechnology company’s stock valued at $441,000 after buying an additional 21,000 shares in the last quarter. Finally, Cutler Capital Management LLC purchased a new stake in shares of Advaxis during the 2nd quarter valued at $130,000. Hedge funds and other institutional investors own 41.90% of the company’s stock.
Several analysts have recently weighed in on the stock. ValuEngine cut shares of Advaxis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. BidaskClub upgraded shares of Advaxis from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Cantor Fitzgerald restated a “buy” rating and set a $19.00 price objective on shares of Advaxis in a research report on Monday, September 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Advaxis in a report on Friday, September 15th.
In other Advaxis news, major shareholder Adage Capital Partners Gp, L.L sold 1,239,323 shares of the firm’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $4.42, for a total value of $5,477,807.66. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Sara Bonstein sold 12,734 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total transaction of $40,621.46. Following the completion of the sale, the chief financial officer now directly owns 244,504 shares in the company, valued at approximately $779,967.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,872,291 shares of company stock worth $8,163,810. 7.21% of the stock is owned by insiders.
Advaxis, Inc. (ADXS) traded down $0.02 during mid-day trading on Thursday, hitting $2.85. 436,241 shares of the company traded hands, compared to its average volume of 690,872. Advaxis, Inc. has a 52 week low of $2.71 and a 52 week high of $10.06.
Advaxis (NASDAQ:ADXS) last released its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $3.43 million. research analysts forecast that Advaxis, Inc. will post -2.21 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Advaxis, Inc. (NASDAQ:ADXS) Holdings Raised by Vanguard Group Inc.” was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/vanguard-group-inc-increases-holdings-in-advaxis-inc-adxs-updated.html.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.